UY28334A1 - Composicion que comprende antagonistas de receptores de progesterona y antiestrógenos puros para la profilaxis y el tratamiento de enfermedades dependientes de hormonas. - Google Patents
Composicion que comprende antagonistas de receptores de progesterona y antiestrógenos puros para la profilaxis y el tratamiento de enfermedades dependientes de hormonas.Info
- Publication number
- UY28334A1 UY28334A1 UY28334A UY28334A UY28334A1 UY 28334 A1 UY28334 A1 UY 28334A1 UY 28334 A UY28334 A UY 28334A UY 28334 A UY28334 A UY 28334A UY 28334 A1 UY28334 A1 UY 28334A1
- Authority
- UY
- Uruguay
- Prior art keywords
- pure
- antistrogens
- prophylaxis
- treatment
- composition
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/30—Oestrogens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/32—Antioestrogens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/36—Antigestagens
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Métodos y usos para prevenir o tratar enfermedades pendientes de hormonas, en particular cáncer de mama,en un mamífero, mediante una combinación de un antagonista de receptores de progesterona, en particular el antagonista de receptores de progesterona 11B-(4-acetilfenil) -17B-hidroxi-17a- (1,1,2,2,2-pentafluoroetil) -estra -4, 9-dien-3-ona o un derivado o análogo del mismo aceptable para uso farmacéutico, y un antiestrógeno puro, en particular un compuesto de la fórmula general I, definida en la memoria descriptiva, p. ej. 11B-fluoro-17a-metil-7a-(5-(metil(8,8,9,9,9-pentafluorononil)amino)pentil)-estra-1,3,5 (10)-trien-3,17B-diol. La invención se relaciona además con composiciones farmacéuticas que comprenden dicha combinación.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/446,165 US20040242551A1 (en) | 2003-05-28 | 2003-05-28 | Composition comprising antiprogestins and pure antiestrogens for prophylaxis and treatment of hormone-dependent diseases |
Publications (1)
Publication Number | Publication Date |
---|---|
UY28334A1 true UY28334A1 (es) | 2004-12-31 |
Family
ID=33450989
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
UY28334A UY28334A1 (es) | 2003-05-28 | 2004-05-27 | Composicion que comprende antagonistas de receptores de progesterona y antiestrógenos puros para la profilaxis y el tratamiento de enfermedades dependientes de hormonas. |
Country Status (18)
Country | Link |
---|---|
US (3) | US20040242551A1 (es) |
EP (2) | EP1628669A1 (es) |
JP (1) | JP2006528226A (es) |
KR (1) | KR20060005412A (es) |
CN (1) | CN1893955A (es) |
AR (1) | AR044450A1 (es) |
AU (1) | AU2004243500A1 (es) |
BR (1) | BRPI0410707A (es) |
CA (1) | CA2524750A1 (es) |
CL (1) | CL2004001317A1 (es) |
EA (1) | EA011506B1 (es) |
MX (1) | MXPA05012841A (es) |
NO (1) | NO20056153L (es) |
PE (1) | PE20050207A1 (es) |
TW (1) | TW200505936A (es) |
UY (1) | UY28334A1 (es) |
WO (1) | WO2004105768A1 (es) |
ZA (1) | ZA200510449B (es) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE10159217A1 (de) * | 2001-11-27 | 2003-06-05 | Schering Ag | 17alpha-Alkyl-17ß-oxy-estratriene und Zwischenprodukte zu deren Herstellung, Verwendung der 17alpha-Alkyl-17ß-oxy-estratriene zur Herstellung von Arzneimitteln sowie pharmazeutische Präparate |
US20040242551A1 (en) * | 2003-05-28 | 2004-12-02 | Schering Ag | Composition comprising antiprogestins and pure antiestrogens for prophylaxis and treatment of hormone-dependent diseases |
KR20060014071A (ko) * | 2003-06-10 | 2006-02-14 | 교와 핫꼬 고교 가부시끼가이샤 | 티아디아졸린 유도체 |
CA2683809A1 (en) * | 2007-04-23 | 2008-10-30 | Bayer Schering Pharma Aktiengesellschaft | Progesterone-receptor antagonist for use in brca alone or as combination with antiestrogen |
US20080261929A1 (en) * | 2007-04-23 | 2008-10-23 | Jens Hoffmann | Combination of progesterone-receptor antagonist together with an aromatase inhibitor for use in brca mediated diseases |
US20080268041A1 (en) * | 2007-04-23 | 2008-10-30 | Jens Hoffmann | Combination of progesterone-receptor antagonist together with none-steroidal antiestrogen for use in brca mediated diseases |
PT2983671T (pt) * | 2013-04-11 | 2019-02-25 | Bayer Pharma AG | Forma farmacêutica de antagonista de recetor de progesterona |
CN115505019B (zh) * | 2022-11-07 | 2024-01-26 | 南宁师范大学 | 7-酰胺取代雌甾类化合物及其制备方法和应用 |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL36654A (en) * | 1970-04-24 | 1974-07-31 | Ciba Geigy Ag | 3-cyclopentyl ethers of 7alpha-methyl-3,16alpha,17(alpha and beta)-trihydroxy-delta 1,3,5(10)-estratriene,their manufacture and estrogenic pharmaceutical compositions containing them |
US4666885A (en) * | 1985-02-08 | 1987-05-19 | Fernand Labrie | Combination therapy for treatment of female breast cancer |
EP0310542B1 (de) * | 1987-10-01 | 1994-06-08 | Schering Aktiengesellschaft | Antigestagen- und antiöstrogenwirksame Verbindungen zur Behandlung hormonabhängiger Tumoren |
DE3733478A1 (de) * | 1987-10-01 | 1989-04-13 | Schering Ag | Antigestagen- und antioestrogenwirksame verbindungen zur geburtseinleitung und zum schwangerschaftsabbruch sowie zur behandlung gynaekologischer stoerungen und hormonabhaengiger tumore |
DE19622457A1 (de) * | 1996-05-24 | 1997-11-27 | Schering Ag | 7alpha-(5-Methylaminopentyl)-estratriene, Verfahren zu deren Herstellung, pharmazeutische Präparate, die diese 7alpha-(5-Methylaminopentyl)-estratriene enthalten sowie deren Verwendung zur Herstellung von Arzneimitteln |
US5866560A (en) * | 1996-08-20 | 1999-02-02 | Schering Ag | 7α-(ξ-aminoalkyl)-estratrienes, process for their production, pharmaceutical preparations which contain these 7α-(ξ-aminoalkyl)-estratrienes as well as their use for the production of pharmaceutical agents |
DE19635525A1 (de) * | 1996-08-20 | 1998-02-26 | Schering Ag | 7alpha-(xi-Aminoalkyl)-estratriene, Verfahren zu deren Herstellung, pharmazeutische Präparate, die diese 7alpha(xi-Aminoalkyl-estratriene enthalten sowie deren Verwendung zur Herstellung von Arzneimitteln |
DE19706061A1 (de) * | 1997-02-07 | 1998-08-13 | Schering Ag | Antigestagen wirksame Steroide mit fluorierter 17alpha-Alkylkette |
PE20000129A1 (es) * | 1997-12-23 | 2000-03-11 | Schering Ag | 11 beta-halogeno-estratrienos sustituidos en 7 alfa, asi como el procedimiento para elaborar preparados farmaceuticos que contienen tales 11 beta-halogeno-estratrienos sustituidos en 7 alfa |
DE19807791A1 (de) * | 1998-02-19 | 1999-08-26 | Schering Ag | Kombinationspräparat aus Östrogen und Antiöstrogen |
PL360157A1 (en) * | 2000-10-18 | 2004-09-06 | Schering Aktiengesellschaft | Use of antiprogestins for the induction of apoptosis in a cell |
IL154975A0 (en) * | 2000-10-18 | 2003-10-31 | Schering Ag | Use of antiprogestins for prophylaxis and treatment of hormone-dependent diseases |
DE10159217A1 (de) * | 2001-11-27 | 2003-06-05 | Schering Ag | 17alpha-Alkyl-17ß-oxy-estratriene und Zwischenprodukte zu deren Herstellung, Verwendung der 17alpha-Alkyl-17ß-oxy-estratriene zur Herstellung von Arzneimitteln sowie pharmazeutische Präparate |
US20040242551A1 (en) * | 2003-05-28 | 2004-12-02 | Schering Ag | Composition comprising antiprogestins and pure antiestrogens for prophylaxis and treatment of hormone-dependent diseases |
-
2003
- 2003-05-28 US US10/446,165 patent/US20040242551A1/en not_active Abandoned
-
2004
- 2004-05-27 WO PCT/EP2004/005732 patent/WO2004105768A1/en not_active Application Discontinuation
- 2004-05-27 MX MXPA05012841A patent/MXPA05012841A/es unknown
- 2004-05-27 EP EP04739401A patent/EP1628669A1/en not_active Withdrawn
- 2004-05-27 BR BRPI0410707-1A patent/BRPI0410707A/pt not_active IP Right Cessation
- 2004-05-27 KR KR1020057022496A patent/KR20060005412A/ko not_active Application Discontinuation
- 2004-05-27 EP EP07090052A patent/EP1834644A3/en not_active Withdrawn
- 2004-05-27 UY UY28334A patent/UY28334A1/es not_active Application Discontinuation
- 2004-05-27 CN CNA2004800145166A patent/CN1893955A/zh active Pending
- 2004-05-27 AU AU2004243500A patent/AU2004243500A1/en not_active Abandoned
- 2004-05-27 US US10/854,761 patent/US20050014736A1/en not_active Abandoned
- 2004-05-27 EA EA200501739A patent/EA011506B1/ru not_active IP Right Cessation
- 2004-05-27 JP JP2006529938A patent/JP2006528226A/ja active Pending
- 2004-05-27 CA CA002524750A patent/CA2524750A1/en not_active Abandoned
- 2004-05-28 CL CL200401317A patent/CL2004001317A1/es unknown
- 2004-05-28 AR ARP040101846A patent/AR044450A1/es unknown
- 2004-05-28 PE PE2004000541A patent/PE20050207A1/es not_active Application Discontinuation
- 2004-05-28 TW TW093115379A patent/TW200505936A/zh unknown
-
2005
- 2005-12-22 ZA ZA200510449A patent/ZA200510449B/en unknown
- 2005-12-23 NO NO20056153A patent/NO20056153L/no not_active Application Discontinuation
-
2007
- 2007-06-18 US US11/764,496 patent/US20070238714A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
PE20050207A1 (es) | 2005-04-28 |
AU2004243500A1 (en) | 2004-12-09 |
KR20060005412A (ko) | 2006-01-17 |
EA011506B1 (ru) | 2009-04-28 |
NO20056153L (no) | 2006-02-22 |
AR044450A1 (es) | 2005-09-14 |
EP1834644A3 (en) | 2007-11-07 |
CL2004001317A1 (es) | 2005-05-06 |
JP2006528226A (ja) | 2006-12-14 |
WO2004105768A1 (en) | 2004-12-09 |
CA2524750A1 (en) | 2004-12-09 |
US20040242551A1 (en) | 2004-12-02 |
WO2004105768A8 (en) | 2006-04-06 |
TW200505936A (en) | 2005-02-16 |
ZA200510449B (en) | 2007-04-25 |
EP1628669A1 (en) | 2006-03-01 |
MXPA05012841A (es) | 2006-02-13 |
CN1893955A (zh) | 2007-01-10 |
EP1834644A2 (en) | 2007-09-19 |
US20070238714A1 (en) | 2007-10-11 |
EA200501739A1 (ru) | 2006-06-30 |
US20050014736A1 (en) | 2005-01-20 |
BRPI0410707A (pt) | 2006-06-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ECSP055574A (es) | Uso de derivados de tio-oxindol en el tratamiento de condiciones relacionadas con hormonas. | |
CY1104981T1 (el) | Χρηση των αντιπρογεστερονων για προληψη και αντιμετωπιση των εξαρτωμενων απο ορμονες ασθενειων | |
ECSP055576A (es) | Uso de derivados de ciclotiocarbamato en el tratamiento de las condiciones relacionadas con hormonas | |
BRPI0516243B8 (pt) | uso de um precursor de esteróide sexual selecionado do grupo que consiste em dehidroepiandrosterona, sulfato de dehidroepiandrosterona, androst-5-eno-3b,17b-diol e 4-androsten-3,17-diona, uso do referido precursor em 5 associação com um modulador de receptor de estrogênio seletivo para proteção uterina e da glândula mamária contra câncer, composição farmacêutica e kit | |
ME00292B (me) | Drospirenon za terapiju zamjene hormona | |
PE20060485A1 (es) | Regimenes anticonceptivos con antagonistas del receptor de progesterona y kits | |
CO6491067A2 (es) | Derivados de 17-hidroxi-17-pentafluoretil-estra-4,9(10)-dien-11arilo, procedimientos para su preparacion y su uso para el tratamiento de enfermedades | |
NO20056153L (no) | Preparat omfattende antiprogestiner og rene antiostrogener for profylakse og behandling av hormon-avhengige sykdommer | |
CY1121190T1 (el) | Δοσολογικη μορφη ανταγωνιστη υποδοχεα προγεστερονης | |
IS2702B (is) | Notkun á (11beta, 17beta)-11-(1,3-bensódíoxól-5-ýl)-17-hýdroxý-17-(1-própýnýl)-estra-4,9-díen-3-ón í meðhöndluninni á alvarlegri geðdeyfðartruflun | |
AR066231A1 (es) | Combinacion de antagonista del receptor de progesterona con atiestrogenos no esteroidales para usar en enfermedades mediadas por brca (genes supresores de tumores) | |
AR066232A1 (es) | Combinacion de antagonista del receptor de progesterona con un inhibidor de la aromatasa para usar en enfermedades mediadas por brca (genes supresores de tumores) | |
CL2008001148A1 (es) | Combinacion farmaceutica que comprende un antagonista del receptor de progesterona 11beta-(4-acetilfenil)-17beta-hidroxi-17alfa-(1,1,2,2,2-pentafluoroetil)-estra-4,9-dien-3-ona y un antiestrogeno; y su uso para el tratameinto del cancer de mama. | |
AR044095A1 (es) | Composicion farmaceutica que comprende un antagonista del receptor de la hormona del crecimiento y un antihipertensivo y uso de los mismos para prepararla | |
AR032371A1 (es) | Uso de antiprogestinas para la profilaxis y el tratamiento de enfermedades dependientes de hormonas | |
TH76790A (th) | สารผสมซึ่งประกอบรวมด้วยโปรเจสเทอโรน-รีเซพเตอร์ แอนทาโกนิสท์ และแอนติเอสโทรเจ็นบริสุทธิ์ สำหรับการป้องกันโรค และการบำบัดโรคที่ต้องพึ่งพาฮอร์โมน | |
TW200733955A (en) | Use of antiprogestins for prophylaxis and treatment of hormone-dependent diseases | |
DOP2005000278A (es) | Composiciones farmaceuticas solidas que comprenden una combinacion de drospirenon, etinilestradiol y un agente surfactante adecuado que presentan una homogeneidad de contend y velocidad de dosolucion asegurada para la droga no micronizada, procedomiento para prepara dicha composicion y uso de esta composicion para preparar un medicamento. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
109 | Application deemed to be withdrawn |
Effective date: 20150522 |